Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
作者信息
Sommerstein Rami, Kochen Michael M, Messerli Franz H, Gräni Christoph
机构信息
Department of Infectious Diseases Bern University Hospital Bern Switzerland.
Institute of Family Medicine University of Freiburg Germany.
出版信息
J Am Heart Assoc. 2020 Apr 7;9(7):e016509. doi: 10.1161/JAHA.120.016509. Epub 2020 Apr 1.
Abstract
摘要
相似文献
1
Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
J Am Heart Assoc. 2020 Apr 7;9(7):e016509. doi: 10.1161/JAHA.120.016509. Epub 2020 Apr 1.
2
Drugs and the renin-angiotensin system in covid-19.
BMJ. 2020 Apr 2;369:m1313. doi: 10.1136/bmj.m1313.
3
COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.
J Mol Cell Cardiol. 2020 Jul;144:12-14. doi: 10.1016/j.yjmcc.2020.04.026. Epub 2020 Apr 24.
4
COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
JAMA. 2020 May 12;323(18):1769-1770. doi: 10.1001/jama.2020.4812.
5
Coronavirus disease 2019 (COVID-19): angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and cardiovascular disease.
Med J Aust. 2020 Jun;212(11):502-503.e1. doi: 10.5694/mja2.50622. Epub 2020 May 21.
6
Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety.
J Drug Target. 2020 Aug-Sep;28(7-8):683-699. doi: 10.1080/1061186X.2020.1797754. Epub 2020 Aug 12.
7
Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.
J Am Coll Cardiol. 2020 Jun 23;75(24):3085-3095. doi: 10.1016/j.jacc.2020.04.028. Epub 2020 Apr 16.
8
The role of ACEIs/ARBs in COVID-19: Friend or foe?
Med Hypotheses. 2020 Sep;142:109810. doi: 10.1016/j.mehy.2020.109810. Epub 2020 May 5.
9
Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.
Drug Discov Ther. 2020;14(4):161-170. doi: 10.5582/ddt.2020.03064.
引用本文的文献
1
Angiotensin-Converting Enzyme Inhibition and/or Angiotensin Receptor Blockade Modulate Cytokine Profiles and Improve Clinical Outcomes in Experimental COVID-19 Infection.
Int J Mol Sci. 2025 Aug 8;26(16):7663. doi: 10.3390/ijms26167663.
2
Impact of Hypertension and Antihypertensive Treatment on COVID-19 Severity: A Retrospective Observational Study in Ternopil Region, Ukraine.
Ther Clin Risk Manag. 2025 Jun 25;21:995-1007. doi: 10.2147/TCRM.S527151. eCollection 2025.
3
Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19.
Front Pharmacol. 2024 Jul 12;15:1414406. doi: 10.3389/fphar.2024.1414406. eCollection 2024.
4
The renin-angiotensin-aldosterone system inhibitor dilemma in COVID-19: balancing cardiovascular benefits and viral risks.
Hypertens Res. 2024 Sep;47(9):2598-2600. doi: 10.1038/s41440-024-01772-x. Epub 2024 Jul 1.
5
Pathogenic mechanisms of cardiovascular damage in COVID-19.
Mol Med. 2024 Jun 19;30(1):92. doi: 10.1186/s10020-024-00855-2.
6
The Epidemiology of COVID-19 Vaccine-Induced Myocarditis.
Adv Med. 2024 Apr 18;2024:4470326. doi: 10.1155/2024/4470326. eCollection 2024.
7
COVID-19 and cardiovascular comorbidities: An update.
Rev Port Cardiol (Engl Ed). 2020 Aug;39(8):417-419. doi: 10.1016/j.repce.2020.06.002. Epub 2020 Dec 16.
8
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
9
Clinical Outcomes of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in COVID-19 Patients With Pre-existing Cardiac Comorbidities: A Literature Review.
Cureus. 2023 Dec 28;15(12):e51244. doi: 10.7759/cureus.51244. eCollection 2023 Dec.
10
COVID-19 susceptibility and severity for dyslipidemia: A mendelian randomization investigation.
Heliyon. 2023 Sep 16;9(9):e20247. doi: 10.1016/j.heliyon.2023.e20247. eCollection 2023 Sep.
本文引用的文献
1
The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020.
China CDC Wkly. 2020 Feb 21;2(8):113-122.
2
Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19.
J Card Fail. 2020 May;26(5):370. doi: 10.1016/j.cardfail.2020.04.013.
3
Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
J Am Heart Assoc. 2020 Apr 7;9(7):e016219. doi: 10.1161/JAHA.120.016219. Epub 2020 Apr 1.
4
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
5
Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005-2016.
Hypertension. 2020 Apr;75(4):973-981. doi: 10.1161/HYPERTENSIONAHA.119.14360. Epub 2020 Mar 9.
6
An interactive web-based dashboard to track COVID-19 in real time.
Lancet Infect Dis. 2020 May;20(5):533-534. doi: 10.1016/S1473-3099(20)30120-1. Epub 2020 Feb 19.
7
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
8
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
9
A Novel Coronavirus from Patients with Pneumonia in China, 2019.
N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.
10
Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
J Am Coll Cardiol. 2018 Apr 3;71(13):1474-1482. doi: 10.1016/j.jacc.2018.01.058.
Zotero 插件